635
Participants
Start Date
June 30, 2014
Primary Completion Date
July 1, 2018
Study Completion Date
August 31, 2033
Hydroxyurea
Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
Hospital Pediátrico David Bernardino, Luanda
Centre Hospitalier Monkole, Kinshasa
KEMRI/Wellcome Trust Research, Kilifi
Ministry of Health Mbale Regional Hospital, Mbale
Children's Hospital Medical Center, Cincinnati
OTHER